Gut Bacteria and Heart Disease: The TMAO Connection

In 2011, a team of researchers at the Cleveland Clinic led by Dr. Stanley Hazen published a study in Nature that changed how cardiologists and microbiome scientists think about heart disease. They discovered that gut bacteria metabolize choline — a nutrient found in eggs and meat — into a compound called trimethylamine (TMA), which the liver then converts to trimethylamine N-oxide (TMAO). Elevated blood levels of TMAO, they found, strongly predicted future cardiovascular events: heart attack, stroke, and cardiovascular death. This finding was provocative because it provided a mechanism connecting the gut microbiome to heart disease that was entirely independent of traditional risk factors like LDL cholesterol. It also reignited the debate about red meat and eggs, because both are rich sources of TMA precursors — not just saturated fat and cholesterol as previously assumed. For patients with SIBO, the TMAO story has a specific and under-discussed relevance: small intestinal bacterial overgrowth may increase TMA production by expanding the population of TMA-producing bacteria in the gut, potentially elevating TMAO levels and cardiovascular risk as a downstream consequence of a gut condition.

The TMAO Pathway: From Diet to Cardiovascular Risk

The TMAO pathway begins with dietary intake of compounds containing a trimethylamine functional group. The main dietary TMAO precursors include choline (found in egg yolks, liver, beef, pork, fish, soybeans, and lecithin), phosphatidylcholine (the phospholipid form of choline abundant in animal foods), L-carnitine (found in red meat, especially beef and lamb, and available as a supplement), and betaine (found in beets, spinach, and wheat germ — also produced in the body from choline metabolism). When these compounds reach the gut, certain bacteria metabolize them to TMA using TMA lyase enzymes. TMA is a gas with a fishy smell — it's responsible for the characteristic odor of fish and is produced in gut fermentation when TMA-containing substrates are present. TMA is rapidly absorbed from the gut into the portal circulation and reaches the liver, where the enzyme flavin-containing monooxygenase 3 (FMO3) oxidizes TMA to TMAO. TMAO then enters systemic circulation and can be measured in blood. Some TMAO is also directly consumed in seafood — fish and shellfish contain preformed TMAO, which is why eating fish transiently raises blood TMAO even though fish consumption is generally associated with cardiovascular protection (the other components of fish — omega-3 fatty acids — appear to outweigh the TMAO effect).

Which Bacteria Produce TMA — and the SIBO Connection

Not all gut bacteria produce TMA. The TMA lyase enzymes required for converting choline and carnitine to TMA are carried by a specific subset of gut organisms. The primary TMA-producing taxa include members of the Firmicutes phylum (including Clostridium, Anaerococcus, and some Streptococcus species), certain Proteobacteria (including Desulfovibrio and Escherichia species), and some Prevotella species. These are not uniformly harmful bacteria — they're part of the normal gut microbiome at appropriate levels. The issue is quantitative and contextual: when these bacteria are overrepresented, or present in unusual locations (like the small intestine in SIBO), TMA production increases. In SIBO, gram-positive and gram-negative bacteria from colonic taxa colonize the small intestine in excess. Among these bacteria are TMA-producing species. Because the small intestine has much higher absorptive surface area than the colon, TMA produced in the small intestine may be absorbed more efficiently into the portal circulation than TMA produced in the colon. This suggests a theoretical pathway by which SIBO could elevate TMAO levels beyond what would be expected from diet alone. To date, direct clinical studies measuring TMAO specifically in SIBO patients are limited, but the mechanistic plausibility is strong, and some functional medicine practitioners have begun measuring TMAO as part of comprehensive SIBO workups.

How TMAO Drives Arterial Plaque and Blood Clotting

TMAO promotes cardiovascular disease through several converging mechanisms. Its effects on cholesterol metabolism and arterial inflammation are most well-established. Cholesterol transport impairment: TMAO inhibits reverse cholesterol transport — the process by which peripheral cells offload excess cholesterol to HDL particles, which then carry it back to the liver for excretion. By impairing this process, TMAO causes cholesterol to accumulate in arterial walls rather than being efficiently cleared. This macrophage cholesterol loading is a key early step in atherosclerotic plaque formation. Foam cell and scavenger receptor upregulation: TMAO increases expression of scavenger receptors (SR-A1 and CD36) on macrophages, making these immune cells absorb oxidized LDL more readily and transform into cholesterol-engorged foam cells — the cellular building blocks of atherosclerotic plaque. Platelet hyperreactivity: Research from the Hazen lab published in Cell in 2017 demonstrated that TMAO directly sensitizes platelets to activation signals, promoting blood clot formation. This mechanism helps explain why high TMAO predicts not just plaque burden but acute cardiovascular events (heart attack and stroke), which are typically triggered by plaque rupture and clot formation. Inflammation and endothelial dysfunction: TMAO activates pro-inflammatory pathways in vascular endothelial cells and macrophages, increasing levels of cytokines and adhesion molecules that accelerate plaque formation and destabilization.

Red Meat, Eggs, and the TMAO Debate

The TMAO research has reignited dietary debates around red meat and eggs with new mechanistic detail — and has also revealed why these debates are complicated. Eggs are the richest dietary source of choline in the Western diet. The Hazen group's original 2011 study showed that consuming two hard-boiled eggs significantly elevated TMAO levels compared to placebo. This seemed to provide a new metabolic mechanism for why eggs might contribute to cardiovascular risk — beyond their cholesterol content, which dietary guidelines had already rehabilitated. However, the full picture is more nuanced. Eggs contain other cardiovascular-protective compounds including lutein, zeaxanthin, omega-3 fatty acids (in pasture-raised eggs), and vitamin D. Large epidemiological studies have shown inconsistent relationships between egg consumption and cardiovascular outcomes, and some meta-analyses find no significant association. For red meat, L-carnitine is the primary TMAO precursor. Red meat — especially beef, lamb, and pork — is very high in carnitine. The Hazen group's 2013 Nature Medicine study showed that L-carnitine supplementation raised TMAO levels in omnivores but not in vegans (who lacked the carnitine-metabolizing bacteria). This finding suggests that the cardiovascular effect of red meat consumption may depend partly on the consumer's gut microbiome — one reason why 'red meat is bad' or 'red meat is fine' as universal statements are both oversimplified. What is clear: high blood TMAO is an independent cardiovascular risk factor. Dietary sources of choline and carnitine are the main inputs, but microbiome composition determines how much TMAO any given person produces from the same diet.

Dietary and Microbiome Strategies to Lower TMAO

If TMAO is a modifiable cardiovascular risk factor, several strategies can meaningfully reduce it. Dietary adjustments include reducing red meat consumption (the primary source of L-carnitine) and substituting plant protein or fish, where cardiovascular protection outweighs TMAO production. Increasing dietary fiber from fruits, vegetables, legumes, and whole grains supports butyrate-producing bacteria that may compete with TMA-producing taxa, shifting the microbiome away from high TMAO production. Resveratrol — found in red wine, grapes, and blueberries — has been shown in studies to inhibit TMA production by gut bacteria and may help reduce TMAO levels. 3,3-Dimethyl-1-butanol (DMB), found naturally in cold-pressed extra-virgin olive oil and balsamic vinegar, inhibits the TMA lyase enzyme in gut bacteria and has been shown to reduce TMAO levels in animal models. Mediterranean-pattern diets (abundant in olive oil, vegetables, legumes, fish, and moderate in red meat) consistently show lower TMAO production in population studies — likely through multiple mechanisms simultaneously. For SIBO patients specifically, effective treatment of the bacterial overgrowth should reduce the population of TMA-producing bacteria in the small intestine and potentially reduce TMAO production from this aberrant location. FMO3 enzyme inhibition: Several pharmaceutical and nutraceutical approaches targeting the hepatic FMO3 enzyme are in development, which would prevent conversion of gut-derived TMA to TMAO. These are in preclinical and early clinical stages as of 2026.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.